Our results indicate a high discrepancy (>60%) in the ESR1/PR status between the primary tumor and EpCAM(+) CTCs, and that ER/PR are expressed at a very low percentage in CTCs in respect to paired primary tumors. The gene discussed is EPCAM; the disease is neoplasm.